Group One Trading’s PharmaCyte Biotech PMCB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-16
Closed -$648 – 7767
2023
Q4
$648 Hold
16
– – ﹤0.01% 7056
2023
Q3
$630 Sell
16
-1,631
-99% -$79K ﹤0.01% 7300
2023
Q2
$89.5K Buy
1,647
+10
+0.6% +$570 ﹤0.01% 4731
2023
Q1
$90.5K Buy
1,637
+58
+4% +$3.24K ﹤0.01% 4384
2022
Q4
$87.6K Sell
1,579
-9,768
-86% -$532K ﹤0.01% 4546
2022
Q3
$517K Hold
11,347
– – ﹤0.01% 3197
2022
Q2
$487K Buy
+11,347
New +$471K ﹤0.01% 3449

Other funds holding PMCB

Group One Trading's PMCB Position: Q3 2026 in Review

Group One Trading sold out of PharmaCyte Biotech (PMCB) in Q3 2026, closing a stake of 26 shares — an estimated $385 sold.

Group One Trading first reported a position in PMCB in Q2 2022 and held it in 6 quarters. The position peaked at $180K in Q3 2022. 20 funds tracked by Wall St. Rank hold PMCB as of Q3 2026.

  • Group One Trading reported no remaining PharmaCyte Biotech position as of Q3 2026 after selling out during the quarter.
  • Group One Trading sold 26 PharmaCyte Biotech shares in Q3 2026, an estimated $385.
  • Group One Trading first reported a position in PharmaCyte Biotech in Q2 2022 and held it in 6 quarters.
  • Group One Trading's PharmaCyte Biotech position peaked at $180K in Q3 2022.
  • 20 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.